Published in J Thromb Haemost on June 01, 2006
Statin therapy and levels of hemostatic factors in a healthy population: the Multi-Ethnic Study of Atherosclerosis. J Thromb Haemost (2013) 2.13
Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ (2011) 1.96
Epidemiology and risk factors for venous thrombosis. Semin Hematol (2007) 1.90
Kidney function and multiple hemostatic markers: cross sectional associations in the multi-ethnic study of atherosclerosis. BMC Nephrol (2011) 1.01
D-dimer level and the risk for thrombosis in systemic lupus erythematosus. Clin J Am Soc Nephrol (2008) 1.00
Disease risk factors identified through shared genetic architecture and electronic medical records. Sci Transl Med (2014) 0.94
Prospective study of plasma D-dimer and incident venous thromboembolism: The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Res (2015) 0.82
Recurrent venous thromboembolism: what is the risk and how to prevent it. Scientifica (Cairo) (2012) 0.82
Management of patients with unprovoked venous thromboembolism: an evidence-based and practical approach. Curr Treat Options Cardiovasc Med (2013) 0.79
Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism. J Thromb Thrombolysis (2015) 0.78
Can anticoagulant treatment be tailored with biomarkers in patients with venous thromboembolism? J Thromb Haemost (2006) 0.76
Update in general internal medicine. J Gen Intern Med (2009) 0.75
A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol (1994) 30.72
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med (1997) 18.85
C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA (2001) 15.85
Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J (1985) 9.28
Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med (1996) 8.57
Incidence of and risk factors for atrial fibrillation in older adults. Circulation (1997) 8.18
Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA (2008) 7.84
Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol (2001) 7.04
An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation (1989) 6.87
DISTRIBUTION OF ASCORBIC ACID IN THE BLOOD AND ITS NUTRITIONAL SIGNIFICANCE. J Clin Invest (1940) 6.38
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA (2001) 5.54
Reduction of bacteriuria and pyuria after ingestion of cranberry juice. JAMA (1994) 5.38
Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med (1993) 5.19
C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation (1998) 4.80
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med (2001) 4.33
Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol (2000) 4.16
A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med (1989) 4.04
Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg-->Gln mutation in the gene for factor V. N Engl J Med (1994) 4.00
Essential role of LAT in T cell development. Immunity (1999) 3.94
Association of moderate alcohol consumption and plasma concentration of endogenous tissue-type plasminogen activator. JAMA (1994) 3.86
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
A prospective study of cigarette smoking and risk of cataract in men. JAMA (1992) 3.72
The relative risk of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses. A case-control study. Microbial Keratitis Study Group. N Engl J Med (1989) 3.63
Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol (1999) 3.36
Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med (1987) 3.34
Light-to-moderate alcohol consumption and risk of stroke among U.S. male physicians. N Engl J Med (1999) 3.21
Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med (1997) 3.13
Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem (2001) 3.12
The incidence of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses. N Engl J Med (1989) 3.11
Intraarterial thrombolysis of lower extremity occlusions: prospective, randomized comparison of forced periodic infusion and conventional slow continuous infusion. Radiology (1993) 3.07
Alveolar-arterial oxygen gradient in the assessment of acute pulmonary embolism. Chest (1995) 2.95
Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation (2000) 2.94
Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol (2001) 2.93
Factor VIII:C inhibitor associated with monoclonal-antibody purified FVIII concentrate. Lancet (1990) 2.91
Epidemiologic aspects of uveal melanoma. Surv Ophthalmol (1988) 2.85
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation (1998) 2.83
Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med (1990) 2.82
Novel clinical markers of vascular wall inflammation. Circ Res (2001) 2.80
Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol (1997) 2.76
Increased pulse pressure and risk of heart failure in the elderly. JAMA (1999) 2.74
Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants. J Thromb Haemost (2007) 2.72
Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group. Circulation (2000) 2.71
Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med (2002) 2.70
Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol (2001) 2.68
Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem (2001) 2.67
Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med (1992) 2.63
The primary prevention of myocardial infarction. N Engl J Med (1992) 2.63
Is it useful to also image the asymptomatic leg in patients with suspected deep vein thrombosis? J Thromb Haemost (2015) 2.62
Noncompliance with congestive heart failure therapy in the elderly. Arch Intern Med (1994) 2.62
Blood pressure and inflammation in apparently healthy men. Hypertension (2001) 2.55
Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst (1993) 2.52
Effect of marathon running on inflammatory and hemostatic markers. Am J Cardiol (2001) 2.50
The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes (2001) 2.47
HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA (1995) 2.46
Non-invasive diagnosis of venous thromboembolism in outpatients. Lancet (1999) 2.46
Frequency and predictors of stroke death in 5,888 participants in the Cardiovascular Health Study. Neurology (2001) 2.41
Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study. J Thromb Haemost (2007) 2.40
Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis (2001) 2.40
Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst (1999) 2.40
Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem (1999) 2.35
Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and race. Am J Public Health (1996) 2.33
Postoperative pulmonary embolism after hospital discharge. An underestimated risk. Arch Surg (1992) 2.33
Discordance between meta-analyses and large-scale randomized, controlled trials. Examples from the management of acute myocardial infarction. Ann Intern Med (1995) 2.31
A prospective study of cigarette smoking and risk of age-related macular degeneration in men. JAMA (1996) 2.27
Survival of spiral ganglion cells in profound sensorineural hearing loss: implications for cochlear implantation. Ann Otol Rhinol Laryngol (1989) 2.24
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost (2013) 2.24
Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in Men. Hypertension (2000) 2.23
Assessing clinical probability of pulmonary embolism in the emergency ward: a simple score. Arch Intern Med (2001) 2.23
Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis. J Lab Clin Med (1992) 2.22
The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens (1997) 2.21
Relations of body fat distribution and height with cataract in men. Am J Clin Nutr (2000) 2.20
Calcium channel blockers and myocardial infarction. A hypothesis formulated but not yet tested. JAMA (1995) 2.15
Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. Arch Intern Med (2000) 2.15
Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial. Radiology (1990) 2.14
Arterial blood gas analysis in the assessment of suspected acute pulmonary embolism. Chest (1996) 2.14
Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center. Arch Intern Med (2001) 2.13
Statin therapy and levels of hemostatic factors in a healthy population: the Multi-Ethnic Study of Atherosclerosis. J Thromb Haemost (2013) 2.13
The renal effects of nonsteroidal anti-inflammatory drugs in older people: findings from the Established Populations for Epidemiologic Studies of the Elderly. J Am Geriatr Soc (1999) 2.12
The pravastatin inflammation CRP evaluation (PRINCE): rationale and design. Am Heart J (2001) 2.12
Performance of helical computed tomography in unselected outpatients with suspected pulmonary embolism. Ann Intern Med (2001) 2.11
Periodontal disease and risk of subsequent cardiovascular disease in U.S. male physicians. J Am Coll Cardiol (2001) 2.11
High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem (2001) 2.06
Clinical uses of low-molecular-weight heparins. Chest (1999) 2.05
Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost (2004) 2.04
Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest (1999) 2.03
HbA1c measured in stored erythrocytes and mortality rate among middle-aged and older women. Diabetologia (2007) 2.03
Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism. Am J Cardiol (1996) 2.01
Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. Arch Intern Med (2001) 2.01
Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem (2001) 2.01
Inherited thrombophilia: Part 1. Thromb Haemost (1996) 2.00
Association of common CRP gene variants with CRP levels and cardiovascular events. Ann Hum Genet (2005) 2.00
Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood (2001) 1.99
A systematic overview of the incidence of posterior capsule opacification. Ophthalmology (1998) 1.98
Large-scale trials of thrombolytic therapy for acute myocardial infarction: GISSI-2, ISIS-3, and GUSTO-1. Ann Intern Med (1993) 1.97
The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol (1985) 1.95